Neoadjuvant versus adjuvant treatment: which one is better for resectable esophageal squamous cell carcinoma?

Table 3 Randomized controlled trials of neoadjuvant chemoradiotherapy versus surgery alone for esophageal squamous cell carcinoma

Study	Histology	SCC (%)	Treatment	n	MS (months)	5-year OS (%)	P value
Bosset and colleagues [30]	SCC	100	C + 37 Gy	143	19	7	NS
			Surgery	139	19	9
Lee and colleagues [32]	SCC	100	CF + 45 Gy	51	28	49^a	NS
			Surgery	50	27	41^a
Burmeister and colleagues [34]	AC/SCC	35	CF + 35 Gy	128	22	17	NS
			Surgery	128	19	13
Natsugoe and colleagues [33]	SCC	100	CF + 40 Gy	22		57	0.58
			Surgery	23		41
Tepper and colleagues [35]	AC/SCC	25	CF + 50.4 Gy	30	54	39	<0.01
			Surgery	26	21	16
Mariette and colleagues [31]	AC/SCC	66	CF + 45 Gy	97	32	49^a	0.68
			Surgery	98	44	55^a
Gaast and colleagues [36]	AC/SCC	24	PC + 41.4 Gy	175	49	59^a	0.011
			Surgery	188	26	48^a

^aThree-year overall survival (OS). AC adenocarcinoma, C cisplatin, CF cisplatin + fluorouracil, MS median survival, NS not significant, PC paclitaxel + carboplatin, SCC squamous cell carcinoma.

ISSN: 1477-7819